Navigation Links
Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
Date:1/15/2008

- Study Subjects Now In Follow-up Period -

EXTON, Pa., Jan. 15 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that injections have been completed in the pivotal Phase III multi-center, double-blind, randomized, placebo-controlled clinical trials evaluating the Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles (Studies IT-A-005 and IT-A-006). Subjects have advanced to the follow-up period of the study.

Isolagen also announced the completion of injections in the Phase II open label study designed to gather further safety and potential application information on the use of the Isolagen Therapy(TM) for the full face (Study IT-A-007). The subjects in this study also have advanced to the follow-up period.

"These are important clinical milestones to Isolagen, especially the advancement of our lead Phase III pivotal wrinkle study to the follow-up period of the trial," said Declan Daly, Chief Executive Officer of Isolagen, Inc.

About Isolagen, Inc.

Isolagen(TM), Inc. (AMEX: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com .

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
2. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
3. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
4. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
5. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
6. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
7. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
8. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
9. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
10. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
(Date:5/4/2016)... Israel , May 4, 2016 ... that BiondVax,s CEO, Dr. Ron Babecoff , will be ... New York City . On Thursday, May ... 2016, a conference presented by Joseph Gunner & ... The BiondVax presentation that Dr. Babecoff will be using ...
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... An essential tool for ... and certain Canadian provinces is now available from the International Association of Industrial ... , The report, Workers’ Compensation Laws as of January 1, 2016, ...
(Date:5/5/2016)... ... 05, 2016 , ... Tim Dieter has announced the latest ... Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center on behalf of ... Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . , Veteran’s Freedom ...
(Date:5/5/2016)... ... ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC in Atlanta, Georgia proudly ... certified and the only facial plastic surgeon in Atlanta to offer Micro-droplet Fat ... stem cells can be used to provide stabilization to hair transplant results or they ...
(Date:5/5/2016)... York) , ... (PRWEB) May 05, 2016 , ... ... talent acquisition startup, HireNurses, on the eve of National Nurses Week (May ... nurses and healthcare employers. With their enrollment into the Talent Tech Lab Virtual Incubation ...
(Date:5/5/2016)... Rochester, NY (PRWEB) , ... May 05, 2016 ... ... app is now available for iOS and Android devices. VisualDx is the ... expanded to include diagnostic support across general medicine. The system speeds diagnosis, ...
Breaking Medicine News(10 mins):